"Accelerating Clinical Development of Bispecific ADCs"

ABL Bio announced on the 30th that it will invest 25 million dollars (approximately 37.7 billion won) in NEOK Bio, a U.S. biotechnology company, through a third-party paid-in capital increase.

ABL Bio Invests 37.7 Billion Won in U.S. NEOK Bio View original image

This marks the second Series A investment in NEOK Bio, following a 30 million dollar (approximately 45.2 billion won) research and development funding provided in September last year. NEOK Bio plans to use the research and development funds received from ABL Bio to accelerate the clinical development of its bispecific antibody-antibody drug conjugate (ADC) pipeline: ABL206 (NEOK001) and ABL209 (NEOK002).


ABL206 is a bispecific ADC based on a topoisomerase I inhibitor that simultaneously targets B7-H3 and ROR1, while ABL209 targets both the epidermal growth factor receptor (EGFR) and MUC1. ABL Bio and NEOK Bio recently received approval from the U.S. Food and Drug Administration (FDA) for Phase 1 Investigational New Drug (IND) applications for both pipelines, and clinical trials targeting solid tumor patients are currently being conducted under the leadership of NEOK Bio. Interim Phase 1 clinical data for both pipelines is expected to be available in 2027.



Lee Sanghoon, CEO of ABL Bio, stated, "NEOK Bio possesses the fastest-developing bispecific ADC among U.S. biotech companies, and it is already attracting significant global attention. To maintain this strength, it is extremely important to further accelerate clinical development."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing